Blog

Dec 11, 2024, 10:33

Pemetrexed plus platinum ± pembrolizumab in untreated metastatic nonsquamous NSCLC

ESMO shared on X:

“For Annals of Oncology Anniversary we highlight this 2023 top-cited paper:’

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 – Annals of Oncology

Authors: D. Rodríguez-Abreu, S.F. Powell, M.J. Hochmair, S. Gadgeel, E. Esteban, E. Felip, G. Speranza, F. De Angelis, M. Dómine, S.Y. Cheng, H.G. Bischoff, N. Peled, M. Reck, R. Hui, E.B. Garon, M. Boyer, T. Kurata, J. Yang, M.C. Pietanza, F. Souza, M.C. Garassino

cancer D. Rodriguez-Abreu E. Esteban E. Felip E.B. Garon ESMO F. De Angelis F. Souza G. Speranza H.G. Bischoff J. Yang M C Garassino M. Boyer M. Dómine M. Reck M.C. Pietanza M.J. Hochmair N. Peled NSCLC OncoDaily Oncology R. Hui S. Gadgeel S.F. Powell S.Y. Cheng T. Kurata

The agenda for the 2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents

Elisabetta Zanon Appointed as the New CEO for the European Cancer Organisation

2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents

Breakthroughs in immunotherapy by Steven O’Day and Alexander Eggermont

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology

Special Coverage